| Mon, 21 Sep 2020 12:20:34: | Flagship Pioneering's 2-becomes-one biotech nabs ex-Pfizer CSO as research lead
|
| Mon, 21 Sep 2020 12:03:57: | Bischofberger's Kronos files for IPO to run pivotal cancer trial
|
| Mon, 21 Sep 2020 12:03:45: | ESMO: Blueprint preps trial of drug targeting triple-mutant EGFR in lung cancer backed by mouse data
|
| Mon, 21 Sep 2020 11:09:23: | ESMO: Adding Elevar's EGFR drug to AstraZeneca's Iressa boosts survival in early lung cancer
|
| Mon, 21 Sep 2020 10:18:28: | Boosting immuno-oncology drugs by recruiting immune messenger cells
|
| Mon, 21 Sep 2020 09:42:34: | Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field
|
| Fri, 18 Sep 2020 15:44:00: | ESMO: Roche's Akt inhibitor scores slight win over J&J's Zytiga
|
| Fri, 18 Sep 2020 15:36:55: | ESMO: Novartis posts data from failed spartalizumab phase 3, reaffirms commitment to PD-1 combos
|
| Fri, 18 Sep 2020 15:24:52: | ESMO: Chi-Med's surufatinib gears up to challenge Novartis, Pfizer with placebo-topping phase 3
|
| Fri, 18 Sep 2020 13:50:31: | ESMO: Early days, but Amgen's BiTE drug in prostate cancer shows encouraging activity
|
| Fri, 18 Sep 2020 12:23:55: | Under pressure, Pfizer, Moderna (and soon AstraZeneca) publish COVID-19 vaccine protocols
|
| Fri, 18 Sep 2020 11:58:54: | Roden, fresh from BMS-Celgene merger, lands VC role at MPM
|
| Fri, 18 Sep 2020 09:56:28: | Brii hires Gilead's China general manager Luo to drive expansion
|
| Fri, 18 Sep 2020 07:16:22: | ESMO: Alkermes' major I-O hope sees progress across early cancer tests
|
| Thu, 17 Sep 2020 18:40:42: | Chutes & Ladders—Olema Oncology brings on AstraZeneca vet Bohen as CEO
|
| Thu, 17 Sep 2020 14:14:33: | ESMO: Amunix's T-cell engagers shrink solid tumors in animal models
|
| Thu, 17 Sep 2020 12:19:20: | Novo, Sanofi VC units lead Lava's $83M series C to fund gamma delta T-cell trials
|
| Thu, 17 Sep 2020 10:33:01: | Moderna lands $100M upfront in deals with Vertex, Chiesi
|
| Thu, 17 Sep 2020 07:53:36: | Trials 'unable to bounce back' after COVID-19 chaos: report
|
| Thu, 17 Sep 2020 07:09:05: | AstraZeneca nabs next-gen oral PCSK9 inhibitor asset from Dogma Therapeutics
|
| Wed, 16 Sep 2020 13:48:41: | Covance teams up with Tempus with time on its mind
|
| Wed, 16 Sep 2020 12:16:42: | Lilly links COVID-19 antibody to reduced hospitalization rate
|
| Wed, 16 Sep 2020 11:28:45: | AstraZeneca's COVID-19 vaccine adverse event has NIH 'very concerned'
|
| Wed, 16 Sep 2020 10:17:20: | Tiny biologic drug to fight COVID-19 shows promise in animal models
|
| Wed, 16 Sep 2020 07:24:27: | After axing leading program, Unity now takes the ax to staff
|
